(a) Experimental timeline. (b) Novelty-induced locomotor response is unaltered in 129S6-B6 TH-Cre+ mice [curve–fit analysis, t = 0–30; F (4, 166) = 0.7092, P=0.5867, n = 18–11] and mice display habituation to the open field chamber [2-way RM ANOVA; time F (3.446, 93.05) = 36.10, P < 0.0001, genotype F (1, 27) =0.6412, P = 0.4303, time by genotype interaction F (5, 135) = 0.2016, P = 0.9613 n = 18–11]. (c) Basal locomotor response following saline injection is not altered in 129S6-B6 TH-Cre+ mice [curve–fit analysis, t = 5–60; F (4, 514) = 2.073, P = 0.0831, n = 18–11]. (d) 129S6-B6 TH-Cre+ mice show attenuated locomotor response to a moderate dose (3.0 mg/kg) of AMPH [curve–fit analysis, t = 5–60; F (4, 514) = 12.21, ****P < 0.0001, n = 18–11]. (e) AMPH-induced stereotypic behavior is not altered in 129S6-B6 TH-Cre+ mice at 8.0 mg/kg dose [2-way RM ANOVA; genotype F (1, 27) =1.916, P = 0.1776, time F (1, 27) =10.54, P = 0.0031, genotype x time interaction F (1,27) =0.2391, P = 0.6288, n = 18–11]. (f) SKF-38393-induced grooming behavior is not altered in 129S6-B6 TH-Cre+ mice [2-way RM ANOVA; drug, F (1, 27) = 20.57, P < 0.0001; genotype, F (1, 27) = 0.324, P = 0.5738, drug x genotype interaction F (1, 27) = 2.097, P = 0.1591, n = 18–11].